Somatic mutations in KEAP1 and NRF2 have been identified in patients with different types of cancers, including lung, head and neck, and gallbladder, and these mutations result in the disruption of the KEAP1–NRF2 interaction and persistent activation of NRF2 through binding with ARE regions [64,65,66]. The gene discussed is NFE2L2; the disease is cancer.